Drug intelligence / Profile preview

EVD-005

Development stage: Preclinical
Lead developer: Evozyne
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

EVD-005 is an engineered cytokine currently in the discovery stage, developed by Evozyne for the treatment of autoimmune diseases. The drug is part of a platform that utilizes protein engineering to create cytokines with 'biased' signaling properties, specifically designed to separate beneficial anti-inflammatory activity from unwanted pro-inflammatory effects. By modifying the protein's interaction with its receptor complex, Evozyne aims to develop a more targeted and safer therapeutic for immune-mediated conditions. As of early 2024, the specific cytokine target has not been publicly disclosed.

Targets

Cr (Chromium)

Beyond the preview

Go deeper on EVD-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVD-005.

Explore the full profile